Citius Oncology, Financials
| CTOR Stock | 0.94 0.06 6.00% |
Investors should never underestimate Citius Oncology,'s ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Citius Oncology,'s cash flow, debt, and profitability to make informed and accurate decisions about investing in Citius Oncology,.
Net Income |
|
Citius |
Understanding current and past Citius Oncology, Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Citius Oncology,'s financial statements are interrelated, with each one affecting the others. For example, an increase in Citius Oncology,'s assets may result in an increase in income on the income statement.
Citius Oncology, Stock Summary
Citius Oncology, competes with Phibro Animal, Procaps Group, Amphastar, Alkermes Plc, and Evolus. Citius Oncology, is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | G8708L104 17331Y109 |
| Older Symbol | TENK |
| Location | New Jersey; U.S.A |
| Business Address | 420 Lexington Avenue, |
| Sector | Life Sciences Tools & Services |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Phone | 347 627 0058 |
Citius Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Citius Oncology,'s current stock value. Our valuation model uses many indicators to compare Citius Oncology, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Citius Oncology, competition to find correlations between indicators driving Citius Oncology,'s intrinsic value. More Info.Citius Oncology, is rated below average in current valuation category among its peers. It also is rated below average in shares outstanding category among its peers creating about 0.02 of Shares Outstanding per Current Valuation. The ratio of Current Valuation to Shares Outstanding for Citius Oncology, is roughly 58.11 . As of 11/28/2024, Common Stock Shares Outstanding is likely to drop to about 57 M. Comparative valuation analysis is a catch-all technique that is used if you cannot value Citius Oncology, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Citius Oncology, Systematic Risk
Citius Oncology,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Citius Oncology, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Citius Oncology, correlated with the market. If Beta is less than 0 Citius Oncology, generally moves in the opposite direction as compared to the market. If Citius Oncology, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Citius Oncology, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Citius Oncology, is generally in the same direction as the market. If Beta > 1 Citius Oncology, moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Citius Oncology, is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Citius has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Citius Oncology,'s financials are consistent with your investment objective using the following steps:- Review Citius Oncology,'s balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Citius Oncology,'s liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Citius Oncology,'s financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Citius Oncology,'s stock is overvalued or undervalued.
Citius Oncology, November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Citius Oncology, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Citius Oncology,. We use our internally-developed statistical techniques to arrive at the intrinsic value of Citius Oncology, based on widely used predictive technical indicators. In general, we focus on analyzing Citius Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Citius Oncology,'s daily price indicators and compare them against related drivers.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 28.8 | |||
| Value At Risk | (10.29) | |||
| Potential Upside | 13.75 |
Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.